The Federal Trade Commission has released its 2013 Annual Highlights, commending some of the high points in the agency’s year.
According to reports, FTC chairwoman Edith Ramirez made a point to emphasize the regulator’s work in pharmaceutical mergers as officials look for ways to crack down on anticompetitive behavior resulting from pay-for-delay schemes, in which brand name companies pay generic companies to delay the release of their cheaper product.
Included in the highlights was the FTC’s challenge of generic drug maker Mylan’s plans to acquire Aguila Specialties in a $1.85 billion deal.
Not surprisingly, the FTC also highlighted its decision to require generic drug maker Actavis to divest rights and assets to four drugs following its acquisition of Warner Chilcott, made for $8.5 billion. That deal was cleared by the regulator late last year.
Perhaps the most significant highlight for the watchdog was the Supreme Court’s ruling last year that allowed pay-for-delay deals to be scrutinized by antitrust regulators in a reversal of an earlier ruling in FTC v. Actavis.
Full Content: The Pharma Letter
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
OpenAI Board Denies Receiving Formal Bid from Elon Musk
Feb 12, 2025 by
CPI
Thomas Kauper, Former DOJ Antitrust Leader, Dies at 89
Feb 12, 2025 by
CPI
BlackRock’s Acquisition of Preqin Secures UK Regulatory Approval
Feb 12, 2025 by
CPI
NFL Sued Over Bluesky Ban by Fans Citing Antitrust Violations
Feb 12, 2025 by
CPI
Warburg Pincus Strikes $1 Billion Deal to Acquire Vermont Information Processing
Feb 12, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon